PP-PF-OTH-GB-0057 | February 2024

Welcome to BayerPRO

Latest resources
Xofigo®▼ (radium-223 dichloride) Resources
PP-XOF-GB-0516, February 2024
NUBEQA®▼ (darolutamide) Resources
PP-NUB-GB-1312, February 2024
mCRPC Patient Case Study
A Nuclear Medicine perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0575, June 2024
mCRPC Patient Case Study
An Oncologist Perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0574, June 2024
Events & webinars
Mirena (52mg levonorgestrel)- The Next Chapter
Dr Paula Briggs and Dr Diana Mansour present Mirena's launch webinar.
Treatment tolerability in mHSPC and nmCRPC
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1703, June 2024
BNMS 2024
Xofigo®▼ (radium-223 dichloride) | NUBEQA®▼ (darolutamide)
Video Resources on the topic of Venous Thromboembolism (VTE)
Expert advice in the management of VTE from National and International thought leaders
RP-XAR-GB-5156, February 2024
Learning Zone
Module 4:
Motivational Interviewing
Module 3
Motivational Interviewing CPD accredited course
Module 2:
Motivational Interviewing CPD accredited course
Module 1:
Motivational Interviewing CPD accredited course
Current treatment landscape and the future for treating mCRC
Stivarga® (regorafenib)
PP-STI-GB-0201, February 2024
Episode 3
The Practicalities of Treatment — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0464, February 2024
Episode 1
Why treat with Xofigo®▼ (radium-223 dichloride)?
PP-XOF-GB-0462, February 2024
Episode 2
Optimising patient identification and referral — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0463, February 2024
NUBEQA®▼ (darolutamide)
In nmCRPC and mHSPC
Stivarga® (regorafenib)
PP-STI-GB-0204, February 2024
Nexavar® (sorafenib) & Stivarga® (regorafenib)
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0564, May 2024

Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.